SCHEMBL2619975

SCHEMBL2619975

O=C(NC(=S)N[C@@]1(c2ccccc2OC(F)(F)F)CCOC[C@H]1CO)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.39
ALDH1A1 P00352 7/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
LMNA P02545 3/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
HSD17B10 Q99714 1/20 0.35
ALOX12 P18054 5/20 0.35
GLA P06280 2/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
RECQL P46063 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1936096 0.86 EPHX1 (0.39) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL7925997 0.86 EPHX1 (0.39) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2109978 0.85 EPHX1 (0.42) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2111012 0.76 EPHX1 (0.44) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2108401 0.75 EPHX1 (0.40) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2108594 0.74 EPHX1 (0.37) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2632348 0.71 BACE1 (0.39)
SCHEMBL15705150 0.71 EPHX1 (0.45) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL6878083 0.70 EPHX1 (0.40) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL6875774 0.70 EPHX1 (0.40) EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946210-B2 Fused aminodihydrothiazine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-02-03 US disclosed
US-8946211-B2 Fused aminodihydrothiazine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-02-03 US disclosed
US-20130203741-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-08-08 US disclosed
US-20120094984-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-19 US disclosed
US-8158620-B2 Fused aminodihydrothiazine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-17 US disclosed
US-8158620-B2 Fused aminodihydrothiazine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-17 US disclosed
US-20100317850-A1 CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-16 US disclosed
US-20090209755-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-20 US disclosed
US-20090209755-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203741-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES BACE1, APP, BACE2 EPHX1 1106/4885ALDH1A1 3053/4885SMN1; SMN2 1291/4885
US-20090209755-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES BACE1, APP, BACE2 EPHX1 1106/4885ALDH1A1 3053/4885SMN1; SMN2 1291/4885
US-20120094984-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES BACE1, APP, BACE2 EPHX1 1106/4885ALDH1A1 3053/4885SMN1; SMN2 1291/4885
US-20100317850-A1 CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE BACE1, APP, BACE2 EPHX1 2197/4885ALDH1A1 2468/4885SMN1; SMN2 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.